Dr Reddy's receives FDA 483 at Indian API plant

By Dan Stanton

- Last updated on GMT

GettyImages/gpointstudio
GettyImages/gpointstudio
The US FDA has issued a Form 483 with four observations to an API facility in Hyderabad, India run by Dr Reddy’s Laboratories.

In a filing with the Bombay Stock Exchange, Indian drugmaker Dr Reddy’s said the US Food and Drug Administration (FDA) completed an audit at an active pharmaceutical ingredient (API) plant in Hyderabad in the Indian state of Telangana Friday.

“We have been issued a Form 483 with four observations which will be addressed comprehensively within stipulated time.”

A company spokesperson could comment neither on the APIs made at the plant nor the observations, beyond what was said to the exchange.

But "we believe that there will not be an delays in the current production,"​ we were told.

According to the firm, the Hyderabad site serves as the corporate centre for Dr. Reddy’s custom pharma services (CPS) business, and includes six commercial API production units, six pilot plants and two kilo labs, and over two million litres of reactor capacity.

The 483 is the latest regulatory action to hit Dr Reddy’s network. In 2017​, a Form 483 with three observations was sent to an API plant in Miryalaguda, Talangana.

Three other Dr Reddy run plants also received 483s last year. They were a finished dosage form site in Duvvada​​, an API plant in Srikakulam​​ and a generic drug facility in Bachupally​​.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us

Products

View more

Webinars